JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gahéry-Ségard, H.
Right arrow Articles by Guillet, J.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gahéry-Ségard, H.
Right arrow Articles by Guillet, J.-G.

 Previous Article  |  Next Article 

Journal of Virology, February 2000, p. 1694-1703, Vol. 74, No. 4
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Multiepitopic B- and T-Cell Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine

Hanne Gahéry-Ségard,1,* Gilles Pialoux,2 Bénédicte Charmeteau,1 Sandrine Sermet,1 Hubert Poncelet,2 Maurice Raux,3 André Tartar,4 Jean-Paul Lévy,1 Helene Gras-Masse,5 and Jean-Gérard Guillet1

Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, INSERM Unité 445, Institut Cochin de Génétique Moléculaire, Université Renée Descartes, Hôpital Cochin, 75014 Paris,1 Hôpital de l'Institut Pasteur, 75015 Paris,2 Laboratoire de Séro-Immunologie Clinique, Pasteur Mérieux Connaught, 27101 Val de Reuil Cedex,3 and CNRS URA1309, Institut de Biologie,4 and UMR 8525 CNRS-Université Lille II,5 Institut Pasteur de Lille, 59021 Lille Cedex, France

Received 29 July 1999/Accepted 10 November 1999

We have attempted to develop an anti-human immunodeficiency virus (HIV) lipopeptide vaccine with several HIV-specific long peptides modified by C-terminal addition of a single palmitoyl chain. A mixture of six lipopeptides derived from regulatory or structural HIV-1 proteins (Nef, Gag, and Env) was prepared. A phase I study was conducted to evaluate immunogenicity and tolerance in lipopeptide vaccination of HIV-1-seronegative volunteers given three injections of either 100, 250, or 500 µg of each lipopeptide, with or without immunoadjuvant (QS21). This report analyzes in detail B- and T-cell responses induced by vaccination. The lipopeptide vaccine elicited strong and multiepitopic B- and T-cell responses. Vaccinated subjects produced specific immunoglobulin G antibodies that recognized the Nef and Gag proteins. After the third injection, helper CD4+-T-cell responses as well as specific cytotoxic CD8+ T cells were also obtained. These CD8+ T cells were able to recognize naturally processed viral proteins. Finally, specific gamma interferon-secreting CD8+ T cells were also detected ex vivo.

* Corresponding author. Mailing address: Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, INSERM Unité 445, Institut Cochin de Génétique Moléculaire, Hôpital Cochin, 27, rue du faubourg Saint-Jacques, 75014 Paris, France. Phone: 33 (0)1 46 33 43 95. Fax: 33 (0)1 44 07 14 25. E-mail: gahery{at}icgm.cochin.inserm.fr.

Journal of Virology, February 2000, p. 1694-1703, Vol. 74, No. 4
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.